GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Capex-to-Operating-Cash-Flow

Zealand Pharma A/S (Zealand Pharma A/S) Capex-to-Operating-Cash-Flow : 0.18 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Zealand Pharma A/S's Capital Expenditure for the three months ended in Dec. 2023 was $-1.52 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $8.71 Mil.

Hence, Zealand Pharma A/S's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2023 was 0.18.


Zealand Pharma A/S Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Zealand Pharma A/S's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Capex-to-Operating-Cash-Flow Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.18

Competitive Comparison of Zealand Pharma A/S's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Zealand Pharma A/S's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Capex-to-Operating-Cash-Flow falls into.



Zealand Pharma A/S Capex-to-Operating-Cash-Flow Calculation

Zealand Pharma A/S's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.475) / -62.28
=N/A

Zealand Pharma A/S's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.52) / 8.708
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma A/S  (OTCPK:ZLDPF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Zealand Pharma A/S Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (Zealand Pharma A/S) Headlines